Get To Know
Kevin Crowley
Senior Managing Director, Investments
Kevin leads CI’s Venture Debt portfolio, making loans to both closely held companies and venture-backed entities.
Since joining Connecticut Innovations in 2006, Kevin has led investments in companies including Cara Therapeutics (IPO), Veradermics (IPO: MANE), HistoRx (acquired by Genoptix), Precipio Diagnostics (IPO), Solais Lighting (acquired by PowerSecure), BioWave, Budderfly, ThayerMahan, Athletic Brewing, Q30, Enko, Perosphere, and dozens of others.
Kevin is a founding member and serves on the board of the UConn Innovation Fund, a partnership among Webster Bank, UConn, and CI that invests in UConn-related technologies.
He managed CI’s $46 million BioFacilities Fund, which invested in wet lab space for bioscience companies, supporting the buildout of more than 300,000 square feet of laboratory space in Connecticut. He also managed CII’s two incubator laboratories at Science Park in New Haven.
Kevin was also involved in the establishment of the Connecticut Stem Cell Fund and managed CI’s pre-seed program, which invests in very early-stage companies through small convertible debt instruments.